Tofacitinib versus methotrexate in rheumatoid arthritis

Area of Science:

• Rheumatology
• Immunology
• Pharmacology

Background:

• Methotrexate is a common first-line treatment for rheumatoid arthritis.
• This study compared tofacitinib (an oral Janus kinase inhibitor) monotherapy with methotrexate monotherapy.
• The study focused on patients treatment-naïve to methotrexate.

Purpose of the Study:

• To evaluate the efficacy and safety of tofacitinib monotherapy compared to methotrexate monotherapy.
• To assess the impact on structural joint damage and clinical response in rheumatoid arthritis patients.
• To determine if tofacitinib is a viable alternative to methotrexate for initial rheumatoid arthritis treatment.

Main Methods:

• A phase 3, randomized study involving 958 patients.
• Patients received either 5 mg or 10 mg of tofacitinib twice daily, or incrementally dosed methotrexate.
• Coprimary end points included change in van der Heijde modified total Sharp score and ACR 70 response at 6 months.

Main Results:

• Tofacitinib groups showed significantly smaller increases in structural joint damage compared to methotrexate (P<0.001).
• Higher proportions of patients achieved ACR 70 response with tofacitinib (25.5% and 37.7%) versus methotrexate (12.0%) (P<0.001).
• Adverse events included herpes zoster (4.0% with tofacitinib vs. 1.1% with methotrexate) and malignancies.

Conclusions:

• Tofacitinib monotherapy is superior to methotrexate in managing rheumatoid arthritis symptoms and inhibiting joint damage progression.
• The clinical benefits of tofacitinib must be weighed against its associated adverse event profile.
• Tofacitinib represents a promising alternative for patients not previously treated with methotrexate.